BUFFALO, NY - Roswell Park Comprehensive Cancer Center ranks in the 96th percentile nationwide for overall patient satisfaction, according to the 2009 Press, Ganey Inpatient Satisfaction Survey, which rates more than 1,000 hospitals across the country.

Roswell Park Comprehensive Cancer Center announced an Institutional Research Grant (IRG) for $180,000 from the American Cancer Society to provide pilot funding for junior-level investigators.

Buffalo, NY - Most patients with anal cancer receive radiation as part of their treatment plan, but the anus is “a very sensitive area of the human body, almost like the fingertips,” notes Gary Yang, MD, Director of Gastrointestinal Radiation Medicine at Roswell Park Comprehensive Cancer Center.

Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check l

Network affiliation will produce exciting and dynamic opportunities for patients and Meadville Medical Center staff

Roswell Park Comprehensive Cancer Center Produces Hip Hop Song and Video to Raise Cancer Awareness Among Generation Y

BUFFALO, NY – Clement Ip, PhD, Professor Emeritus in Oncology from the Department of Cancer Prevention and Control at Roswell Park Comprehensive Cancer Center, is the principal investigator of a $5.4M P01 grant from the National Institutes of Health to study the role of finasteride and selenium i

Charlie Wilson, famed R&B artist widely known as both an influential solo artist and lead vocalist for the GAP band in the 1980’s, along with several health experts and cancer survivors, joined forces on Friday, November 27th at Roswell Park Comprehensive Cancer Center to target local African

BUFFALO, NY – Roswell Park Comprehensive Cancer Center physician Roberto Pili, MD, has been awarded an R01 grant from the National Institutes of Health to study the role of histone deacetylase (HDAC) inhibitors in treating renal cell carcinoma (RCC). The two-year grant is for $675,000.